Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

NCT05440708 is registered in ClinicalTrials.gov with Tvardi Therapeutics, Incorporated as lead sponsor.

NCT NCT05440708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05440708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Lead sponsor
Tvardi Therapeutics, Incorporated
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 23, 2023
Completion date
March 10, 2027
Enrollment
193 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma